Searched for
GLOBAL BIOPHARMA INDUSTRY
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplierIndia's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...
Karnataka plans $400 billion Bengaluru region economy by 2037Karnataka plans to expand Bengaluru's economy to $400 billion by 2037. The master plan aims to create millions of new jobs and boost key se...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the possibility of hostilities resuming in the Gulf region, focus on risk management in the market. Why? Because fresh hostilities wi...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Biocon's Shaw says Budget boosts India’s health and innovation agendaThe Union Budget is making a significant investment in India's health and innovation. Biopharma has been identified as a key strategic sect...
- Budget 2026 bets on biopharma, SME capital to drive resilient growth: Industry leadersThe Union Budget 2026-27 focuses on fortifying the Indian economy against global volatility through strategic investments in technology, he...
- Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitionsIndia's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...
- Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturingUnion Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...
- Budget 2026: Sitharaman’s six-point plan to propel India’s next growth phaseUnion Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- PharmNXT Biotech unveils first integrated manufacturing unit for single use bioprocessing systemsThe new facility was launched at the PharmNXT Biotech LLP, the company’s facility in Chakan, Pune.
- Top government officials, leaders from industry, academicians to take part in India-US Biopharma and Healthcare SummitNITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- Telangana plans country’s first biopharma hubTelangana government proposes to set up India’s first Biopharma-Hub to provide support to the biopharma research and development activities.
- Policy, infrastructure main hurdles in Indian pharma R&D: ReportThe McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
Load More
